

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
30 June 2005 (30.06.2005)

PCT

(10) International Publication Number
WO 2005/058871 A1

(51) International Patent Classification⁷: **C07D 401/06**,
A61K 31/4184, C07D 413/14, A61P 11/00, 31/12 //
(C07D 401/06, 235:00, 213:00)

TIMMERMAN, Philip, Maria, Martha, Bern [BE/BE];
Vijversstraat 211, B-3550 Hasselt (BE).

(21) International Application Number:
PCT/EP2004/053620

(74) Agent: **WANTE, Dirk**; Tibotec-Virco Comm. VA, Gen-
eraal De Wittelaan L 11B 3, B-2800 Mechelen (BE).

(22) International Filing Date:
20 December 2004 (20.12.2004)

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
03104810.1 18 December 2003 (18.12.2003) EP
60/567,182 30 April 2004 (30.04.2004) US
04105312.5 26 October 2004 (26.10.2004) EP

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **TI-
BOTEC PHARMACEUTICALS LTD.** [IE/IE]; Little
Island, Co Cork (IE).

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): **BONFANTI,**
Jean-François [FR/FR]; 4 bis Route Nationale, F-27430
Andé (FR). **ANDRIES, Koenraad, Jozef, Lodewijk**
[BE/BE]; Oosteneinde 9, B-2340 Beerse (BE). **FORTIN,**
Jérôme, Michel, Claude [FR/FR]; 22, rue des acacias,
F-27460 Igoville (FR). **MULLER, Philippe** [FR/FR];
17 Route d'Herqueville, F-27430 Andé (FR). **DOU-
BLET, Frédéric, Marc, Maurice** [FR/FR]; 1646, Route
de Neufchatel, F-76230 Isneauville (FR). **MEYER,**
Christophe [FR/FR]; 428 rue de Gouy, F-76520 Les
Authieux s/l Port St Ouen (FR). **WILLEBRORDS, Rudy,**
Edmond [BE/BE]; Vaartstraat 70, B-2330 Merksplas
(BE). **GEVERS, Tom, Valerius, Josepha** [BE/BE];
Burgemeester Bossaertlaan 17, B-2350 Vosselaar (BE).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted
a patent (Rule 4.17(ii)) for the following designations AE,
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ,
CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE,
EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM,
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA,
ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ,
NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT,
BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR,

[Continued on next page]

(54) Title: MORPHOLINYL CONTAINING BENZIMIDAZOLES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION



(57) Abstract: The present invention concerns morpholinyl containing benzimidazoles having inhibitory activity on the replication of the respiratory syncytial virus and having the formula (I), a prodrug, N-oxide, addition salt, quaternary amine, metal complex or stereochemically isomeric form thereof wherein G is a direct bond or optionally substituted C₁₋₁₀alkanediyl; R¹ is Ar¹ or a monocyclic or bicyclic heterocycle Q is R⁷, pyrrolidinyl substituted with R⁷, piperidinyl substituted with R⁷ or homopiperidinyl substituted with R⁷; one of R^{2a} and R^{3a} is selected from halo, optionally mono- or polysubstituted C₁₋₆alkyl, optionally mono- or polysubstituted C₂₋₆alkenyl, nitro, hydroxy, Ar², N(R^{4a}R⁴), N(R^{4a}R^{4b})sulfonyl, N(R^{4a}R^{4b})carbonyl, C₁₋₆alkyloxy, Ar²oxy, Ar²C₁₋₆alkyloxy,

carboxyl, C₁₋₆alkyloxycarbonyl, or -C(=Z)Ar²; and the other one of R^{2a} and R^{3a} is hydrogen; in case R^{2a} is different from hydrogen then R^{2b} is hydrogen, C₁₋₆alkyl or halogen and R^{3b} is hydrogen; in case R^{3a} is different from hydrogen then R^{3b} is hydrogen, C₁₋₆alkyl or halogen and R^{2b} is hydrogen. It further concerns the preparation thereof and compositions comprising these compounds, as well as the use thereof as a medicine.



HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG)

- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii)) for all designations
- of inventorship (Rule 4.17(iv)) for US only

Published:

- with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.